HD-OPM Archive
Topics › Insulin resistance & diabetes

SGLT2 inhibitors consistently raise hemoglobin and hematocrit, a possible anemia benefit

Louis Nervegna · Oct 24, 2026 · ♥ 1 reactions · 0 comments · original Facebook post
Insulin resistance & diabetesKidney healthHeart rhythm & heart failure
AI summary & key facts

A JAMA editorial presented at Kidney Week says SGLT2 inhibitors consistently raise hemoglobin and hematocrit in people with cardiovascular disease, heart failure or chronic kidney disease, with or without diabetes. This may contribute to anemia management on top of their established cardiovascular and kidney benefits.

SGLT2 inhibitors increase hemoglobin and hematocrit, which can be a side benefit for patients prone to anemia.

#sglt2HD #hematocritHD #hemoglobinHD #anemiaHD

Research cited

Shared from JAMA · original post

Presented at #KidneyWk:

💬 Editorial by Kai-Uwe Eckardt, MD, and Mark Koury, MD: #SGLT2 inhibitors were developed for glycemic control but also consistently increase hemoglobin and hematocrit across patients with cardiovascular disease, heart failure, or chronic kidney disease, with or without diabetes. This additional effect may contribute to multimodal anemia management while accompanying the established cardiovascular and kidney benefits of this drug class.

Paper · JAMAJAMA articleja.maMay be an image of text
← newer: Blood NAD levels do not fall with age, so commercial NAD bloolder: Statin use linked to 15% lower risk of open-angle glaucoma a →